Comparison of Development Trends Between Fetal Bovine Serum and Serum-Free Media

The Role of Fetal Bovine Serum in Traditional Culture Systems

Fetal bovine serum (FBS), due to its rich content of substances required for cell growth, has long been used as an important additive for mammalian cell culture and is widely applied in vaccine development, monoclonal antibody production, cell biology research, and other fields. Its advantage lies in its broad applicability, as it can support the growth of various adherent and suspension cells. However, FBS is a natural biological source material with incompletely defined components, and differences may exist between batches, which poses certain challenges to process stability and quality control.

Technical Advantages and Boundaries of Serum-Free Media

As biopharmaceuticals place higher demands on process consistency and safety, serum-free media and chemically defined media have gradually gained wider adoption. Serum-free systems generally have more clearly defined components, which facilitates downstream purification, viral clearance validation, and control of adventitious agents, while also reducing the potential risks associated with animal-derived components. However, serum-free culture is not suitable for all cell types. Some primary cells, stem cells, and certain production cell lines may still require FBS or serum substitutes to maintain proliferation and function. Therefore, whether to switch to a serum-free system should be determined comprehensively based on cell characteristics, process objectives, and validation data.

Research scenarios: FBS remains a common choice, but attention must be paid to source compliance and batch-to-batch stability.

Biopharmaceutical scenarios: An increasing number of companies are inclined to adopt serum-free or low-serum processes to meet regulatory requirements for traceability.

In vitro diagnostic scenarios: For the culture of certain cell lines, it is necessary to evaluate whether components in serum interfere with detection markers.

Key Considerations from Selection to Compliance

When selecting FBS, emphasis should be placed on reviewing the inspection reports, certificates of origin, and quality system documentation provided by suppliers. For research and production involving human medicinal products or medical devices, attention should also be paid to the traceability of animal-derived materials and compliance with biosafety-related requirements. Promotional language or price alone should not be used as the basis for judgment. If a project is in the later stages of process development, the possibility of gradually reducing serum concentration or transitioning to a serum-free system can be evaluated, along with necessary comparability studies.

Future Trend: Long-Term Coexistence of Both Systems

In the short term, FBS will continue to play a role in basic research and some production processes, while serum-free media will continue to develop in large-scale biopharmaceutical production. Laboratories and companies should establish scientific material evaluation mechanisms, clarify the requirements for culture systems at each stage, and avoid blindly following trends when making switches. Through pilot testing, stability observation, and documentation, a balance among performance, cost, and compliance can be gradually identified.